MIAMI, June 30, 2026 /PRNewswire/ -- GoTu Technology, the nation's leading dental talent marketplace

Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page a

Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on ana

BTIG analyst David Larsen upgrades Henry Schein (NASDAQ:HSIC) from Neutral to Buy and announces $

Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to offi

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the pri

Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers t

Henry Schein (NASDAQ:HSIC) affirms FY2026 Adj EPS guidance from $5.23-$5.37 to $5.23-$5.37 vs $5.32

Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.32 per share which beat the analyst con

Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and ra

Top analysts change outlook on top names, check analyst ratings page for all changes. Keybanc initia

Citigroup analyst Daniel Grosslight initiates coverage on Henry Schein (NASDAQ:HSIC) with a Buy r

Evercore ISI Group analyst Elizabeth Anderson maintains Henry Schein (NASDAQ:HSIC) with a Outperf

Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office

Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30%

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:HSIC) with a Outperfor

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the pri

JP Morgan analyst John Stansel maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises

Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises t

Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and ra

Wells Fargo analyst Vik Chopra maintains Henry Schein (NASDAQ:HSIC) with a Equal-Weight and raise

Evercore ISI Group analyst Elizabeth Anderson maintains Henry Schein (NASDAQ:HSIC) with a Outperf

Leerink Partners analyst Michael Cherny maintains Henry Schein (NASDAQ:HSIC) with a Market Perfor

Henry Schein beats Q4 earnings and sales estimates, guides steady 2026 growth as shares climb nearly

Henry Schein (NASDAQ:HSIC) is looking for FY2026 Adj EPS of $5.23-$5.37 vs $5.30 analyst estimate. s

Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.34 per share which beat the analyst con

Baird analyst Jeff Johnson upgrades Henry Schein (NASDAQ:HSIC) from Neutral to Outperform and rai

Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises t

Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S.Henry Schein, Inc. (NASDAQ:

Henry Schein, Inc. (NASDAQ:HSIC) (the "Company"), the world's largest provider of health

Barclays analyst Glen Santangelo initiates coverage on Henry Schein (NASDAQ:HSIC) with a Overweig

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as invest

Bank of America is pointing investors toward 16 overlooked stocks with strong fundamentals and no di

On "Mad Money," Cramer discusses Henry Schein, Bloom Energy, Tyler Technologies, Boeing and

JP Morgan analyst John Stansel maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:HSIC) with a Outperfor

Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and ra

Wells Fargo analyst Vik Chopra maintains Henry Schein (NASDAQ:HSIC) with a Equal-Weight and raise